Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos G Grijalva

Showing results (1-10 of 387) with videos related to

Pageof 39
Sort By:
The Lancet. Infectious Diseases|November 30, 2013
Decrease in antibiotic use, an added benefit of PCVsCarlos G Grijalva
Vaccine|June 23, 2009
Recognising pneumonia burden through preventionCarlos G Grijalva
American Journal of Respiratory and Critical Care Medicine|September 2, 2015
Is Pneumonia a Risk Factor or a Risk Marker for Long-Term Mortality?Carlos G Grijalva
Thorax|January 11, 2018
Countrywide demonstration of adult protection derived from infant immunisationCarlos G Grijalva
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2021
What Fraction of Adult Community-Acquired Pneumonia Is Caused by the Pneumococcus? New Insights from SpainCarlos G Grijalva
The Journal of Infectious Diseases|October 5, 2013
Distribution of pneumococcal serotypes in adult pneumococcal pneumonia cases: filling the evidence gap to inform vaccination policiesMarie R Griffin, Carlos G Grijalva
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2019
To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination ProgramAndrew D Wiese, Carlos G Grijalva
Current Opinion in Pediatrics|December 31, 2010
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in childrenCarlos G Grijalva, Stephen I Pelton
The Lancet. Respiratory Medicine|August 16, 2014
Prevention of invasive pneumococcal diseases: beyond culturesCarlos G Grijalva, Marie R Griffin
The New England Journal of Medicine|October 25, 2013
Hospitalizations after a decade of pneumococcal vaccinationMarie R Griffin, Carlos G Grijalva
Pageof 39

Showing results (1-10 of 387) with videos related to

Sort By:
Pageof 39
The Lancet. Infectious Diseases|November 30, 2013
Decrease in antibiotic use, an added benefit of PCVsCarlos G Grijalva
Vaccine|June 23, 2009
Recognising pneumonia burden through preventionCarlos G Grijalva
American Journal of Respiratory and Critical Care Medicine|September 2, 2015
Is Pneumonia a Risk Factor or a Risk Marker for Long-Term Mortality?Carlos G Grijalva
Thorax|January 11, 2018
Countrywide demonstration of adult protection derived from infant immunisationCarlos G Grijalva
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2021
What Fraction of Adult Community-Acquired Pneumonia Is Caused by the Pneumococcus? New Insights from SpainCarlos G Grijalva
The Journal of Infectious Diseases|October 5, 2013
Distribution of pneumococcal serotypes in adult pneumococcal pneumonia cases: filling the evidence gap to inform vaccination policiesMarie R Griffin, Carlos G Grijalva
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2019
To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination ProgramAndrew D Wiese, Carlos G Grijalva
Current Opinion in Pediatrics|December 31, 2010
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in childrenCarlos G Grijalva, Stephen I Pelton
The Lancet. Respiratory Medicine|August 16, 2014
Prevention of invasive pneumococcal diseases: beyond culturesCarlos G Grijalva, Marie R Griffin
The New England Journal of Medicine|October 25, 2013
Hospitalizations after a decade of pneumococcal vaccinationMarie R Griffin, Carlos G Grijalva
Pageof 39